Clinical trials: Cardiovascular Disease Prevention
Hypertension, MTHFR 677 CC or CT Genotype
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
This is a multi-center, randomized, double-blind, double-dummy, controlled clinical trial. This trial will include 32,000 Chinese men and women with hypertension (H-type hypertension), MTHFR 677 CC or CT genotype, elevated plasma…
- Conditions
- Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
- Trial name
- CSPPT2-CC/CT (NCT04974138)
- Testing
- Amlodipine besylate, Amlodipine besylate and folic acid
- Where
- 20 sites in China
- Volunteers
- 32,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Non-valvular Atrial Fibrillation (NVAF)
Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
In this study researchers want to learn more about on the safety of the drug Xarelto. The study will enroll patients for whom the treating doctor are prescribing Xarelto for the prevention of brain attack or the prevention of…
- Trial name
- XARETO (NCT04356989)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Taiwan
- Volunteers
- 493 people
- Sponsor
- Bayer
Atrial Fibrillation
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population
- Trial name
- NCT00448214
- Testing
- YM150, warfarin
- Where
- 18 sites in Australia, Hong Kong and 8 more
- Volunteers
- 448 people
- Sponsor
- Astellas Pharma Inc
Hereditary Angioedema Types I and II
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema.
- Trial name
- NCT01912456
- Testing
- Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor
- Where
- 39 sites in United States, Australia and 8 more
- Volunteers
- 90 people
- Sponsor
- CSL Behring
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Thromboembolism
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery
- Trial name
- PEARL-1 (NCT00408239)
- Testing
- YM150, enoxaparin
- Where
- 19 sites in Indonesia, Japan and 6 more
- Volunteers
- 367 people
- Sponsor
- Astellas Pharma Inc
Thrombosis
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are…
- Trial name
- NCT02671461
- Testing
- BMS-986141, Aspirin
- Where
- 33 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Aortic Aneurysm, Abdominal
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR)…
- Trial name
- NCT06029660
- Testing
- IMPEDE-FX RapidFill Implants, EndoVascular Aneurysm Repair
- Where
- 49 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Shape Memory Medical, Inc.
Venous Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and…
- Trial name
- ADOPT (NCT00457002)
- Testing
- Apixaban, Enoxaparin
- Where
- 296 sites in United States, Argentina and 33 more
- Volunteers
- 6,758 people
- Sponsor
- Bristol-Myers Squibb
Embolism
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
Acutely ill immobilized patients are at a high risk for thromboembolic events including deep venous thrombosis or pulmonary embolism.
- Trial name
- NCT00311753
- Testing
- Certoparin, Heparin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 342 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Arterial Disease
Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
The PID-PAB study aims to test the efficacy of the European Guidelines on Cardiovascular Disease Prevention in patients with peripheral arterial disease.
- Trial name
- PID-PAB (NCT00761969)
- Testing
- Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice
- Where
- Slovenia
- Volunteers
- 1,455 people, healthy volunteers welcome
- Sponsor
- KRKA
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total knee replacement surgery.
- Trial name
- NCT00917254
- Testing
- YM150, Enoxaparin
- Where
- 13 sites in Japan, Taiwan and 1 more
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Cerebral Infarction
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral…
- Trial name
- NCT00234065
- Testing
- Cilostazol, Aspirin
- Where
- Japan
- Volunteers
- 2,800 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atrial Fibrillation
Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72…
- Trial name
- NCT00526136
- Testing
- Vernakalant (oral)
- Where
- 152 sites in Australia, Belgium and 22 more
- Volunteers
- 735 people
- Sponsor
- Advanz Pharma
Turner's Syndrome
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years.
- Trial name
- NCT01066052
- Testing
- r-hGH
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hereditary Angioedema
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
The main aims of this study are to learn how lanadelumab moves through a child's body and if the children have any medical problems from lanadelumab.
- Trial name
- SPRING (NCT04070326)
- Testing
- Lanadelumab
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- Shire
Atherosclerotic Disease
CAPTURE Study (Polyglucosamine for Cardio & Atherosclerosis Prevention and Treatment Via Fat Uptake REduction)
This clinical investigation is intended to confirm the application of a new intended purpose and a new indication for an already certified medical device.
- Trial name
- CAPTURE (NCT06910111)
- Testing
- Polyglucosamine
- Where
- 3 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Certmedica International GmbH
Hereditary Angioedema (HAE)
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants…
- Trial name
- CHAPTER-4 (NCT06679881)
- Testing
- Deucrictibant
- Where
- 67 sites in United States, Argentina and 21 more
- Volunteers
- 170 people
- Sponsor
- Pharvaris Netherlands B.V.
Atrial Fibrillation
Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
1600 AF patients receiving Pradaxa or VKA for stroke prevention will be followed up for 12 months in quarterly visits. Prescriptions, adverse events and (if applicable) reasons for definitive treatment discontinuation will be…
- Trial name
- NCT02240667
- Testing
- Dabigatran etexilate, Vitamin K antagonists
- Where
- Germany
- Volunteers
- 1,506 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden.
- Trial name
- NCT05819112
- Where
- United States
- Volunteers
- 14,799 people
- Sponsor
- Sanofi